PCI Biotech has announced the start of an evaluation process to consider a structured wind-up of the company. This follows the earlier decision to halt all research and development activities, as communicated on 8 January 2026. The company continues to explore various strategic options during this period.
The assessment aims to determine the best course of action for the company’s future, taking into account its current position and ongoing strategic review.
**Why this matters**
The evaluation of a structured wind-up signals a significant shift in PCI Biotech’s operations and strategy. Stakeholders, including investors and partners, will be closely watching the outcome, as it may impact the company’s assets, liabilities, and overall market presence.